CMPS logo

CMPS
COMPASS Pathways

8,153
Mkt Cap
$662.41M
Volume
1.07M
52W High
$8.90
52W Low
$2.25
PE Ratio
-2.57
CMPS Fundamentals
Price
$6.88
Prev Close
$6.90
Open
$6.73
50D MA
$6.94
Beta
1.35
Avg. Volume
1.48M
EPS (Annual)
-$2.30
P/B
17.62
Rev/Employee
$0.00
$121.81
Loading...
Loading...
News
all
press releases
Compass Pathways (NASDAQ:CMPS) Price Target Raised to $70.00 at HC Wainwright
HC Wainwright lifted their price target on Compass Pathways from $40.00 to $70.00 and gave the stock a "buy" rating in a report on Monday...
MarketBeat·3h ago
News Placeholder
More News
News Placeholder
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders PR Newswire VANCOUVER, BC, Feb. 26, 2026...
PR Newswire·4d ago
News Placeholder
Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were...
Business Wire·4d ago
News Placeholder
Compass Pathways (NASDAQ:CMPS) Stock Price Down 6.9% - Here's Why
Compass Pathways (NASDAQ:CMPS) Trading Down 6.9% - Time to Sell...
MarketBeat·5d ago
News Placeholder
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity PR Newswire NEW YORK, Feb. 24, 2026...
PR Newswire·6d ago
News Placeholder
Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the TD...
Business Wire·6d ago
News Placeholder
Magic Mushrooms, Hard Cash: Compass Pathways' Trial Win, Fast Raise
See what Compass Pathways' Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the near-term setup...
MarketBeat·10d ago
News Placeholder
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year?
Here is how Auna S.A. (AUNA) and COMPASS Pathways PLC Sponsored ADR (CMPS) have performed compared to their sector so far this year.
Zacks·10d ago
News Placeholder
Compass Pathways (NASDAQ:CMPS) Sees Unusually-High Trading Volume - What's Next?
Compass Pathways (NASDAQ:CMPS) Sees Unusually-High Trading Volume - Should You Buy...
MarketBeat·11d ago
News Placeholder
The FDA could approve key component of magic mushrooms as a depression treatment
Compass Pathways' proprietary form of psilocybin has passed a pair of clinical trials, sending stock upwards...
Quartz·11d ago
<
1
2
...
>

Latest CMPS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.